Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Affinity Mediaworks Corp    

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Affinity Mediaworks Corp : Affinity Medical Pushes Forward with Promising Cancer Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
08/26/2013 | 02:55pm CET

Company Establishes Relationship with Renowned Delta Institute International

New Brunswick, Canada - (ACCESSWIRE) - August 26, 2013 - Affinity Medical Corp. (OTCBB: AFFW), (OTCQB: AFFW), a company focused on creating a network of treatment centers that offer patients homeopathic, alternative treatments of the BX Protocol (BX Antitoxin/Energy Catalyst), which has been a proven alternative solution to combat cancer, diabetes, rheumatoid arthritis, lymes, parkinson's and many other illnesses through the use of the BX Antitoxin Protocol. Affinity Medical announced today its relationship with the renowned Delta Institute International, leaders in providing remedial outcomes in cancer related pathologies. The relationship will allow Affinity to provide patient-centric treatment environments to better the fight against life-crippling diseases like cancer, arthritis, and diabetes through the use of the BX Antitoxin Protocol and make leading-edge treatments more accessible to patients worldwide. The announcement was made by Mr. Timo Strattner, CEO of Affinity Medical Corp.

The mutually beneficial agreement enables the Delta Institute to be Affinity's clinical associate, providing R&D, treatment plan evaluation, and clinical supervision. The Delta Institute will work closely on active case management, in addition to providing advice and recommendations on Affinty's treatment center set-ups, patient diagnoses, and treatment plans based on their 20 years of experience and knowledge with the BX Antitoxin Protocols which target and attack cancer and other autoimmune diseases at a cellular level by disabling and dismantling mitochondrial function. The agreement also affords Affinity Medical Corp "reach-back" capabilities to more than 5,000 patient case files, plus ongoing clinical trials.

Affinity aims to consolidate this valuable information and experience in providing BX Antitoxin, which targets and attacks cancer and other autoimmune diseases at a cellular level by disabling and dismantling mitochondrial function. In the beginning of cancer, the pleomorphic stealth bacterium enter the health cells or pre-cancerous cells, altering or impairing the mitochondria [the cell's energy center] to change the cells from oxygen dependent to low oxygen dependent, allowing them to exist in low oxygen conditions, and changes the apoptosis, thus allowing the cells to live without normal death, enabling their multiplication. Through a complex mechanism of action, the BX Antitoxin provides interference between the cancer microbe and cellular mitochondria. By such interference, the process is dismantled, and apoptosis is enabled again, with cancer cell death occurring. . During this process, cell by cell, the BX Antitoxin moves in causing a chain reaction, like a multi-car pile-up, stopping the cancer cells to continue to proliferate. Thus, it causes massive and permanent cancer death.

Statistics from researchers say 95% of those in Stages I, II, III cancers could have complete resolve; those in Stage IV could have a 75% chance of complete resolve and those in Hospice could have a 40 to 50 % chance of complete resolve. This is quite impressive and far surpasses any conventional therapy. The BX Antitoxin targets the cancer from the inside out, stopping its growth [multiplication] and restoring healthy function [stopping recurrence]. No one can be told there is no hope. There is and it is here, today. For more information, please visit http://www.affinitym.com/.

About Affnity Medical Corp

Affinity Medical is focused on creating a network of patient-centric treatment centers dedicated to offering patients homeopathic, alternative treatments of the BX Antitoxin Protocol, which has been proven solution to combat cancer, arthritis, diabetes, and other illnesses. The company's mission is to make its revolutionary treatments readily and easily available to patients across the globe through affiliated and accredited medical networks and clinics. Affinity Medical pursues this opportunity to become the dominant point of reference in its region of operations for the medical communities and their patients that wish to use alternative treatment protocols, such as the BX Antitoxin Protocol.

Investor Questions:

Phone +1 800-653-5374
[email protected]

Forward-Looking Statements:

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Affinity MediaWorks and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Forward-looking statements may be identified by words such as "goals," "plans," "believes," "will," "expects" and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. This document is not a solicitation to invest. Investors are cautioned not to place any undue reliance on any forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions the occurrence of unanticipated events or changes to future operating results.

Important Disclaimers

Affinity as a whole does not market, promote or advertise this treatment in the USA nor to US-Citizens. All treatments are managed through our Non-US based subsidiaries and partner firms outside the USA.


FDA Required Disclaimer For Sites That Do Not Endorse Chemotherapy: This web site is for educational purposes only. It is not intended as a substitute for the diagnosis, treatment and advice of a qualified licensed professional. This site offers people medical information and tells them their alternative medical options, but in no way should anyone consider that this site represents the "practice of medicine." This site assumes no responsibility for how this material is used. Also note that this website frequently updates its contents, due to a variety of reasons, therefore, some information may be out of date. The statements regarding alternative treatments for cancer have not been evaluated by the FDA.


Phone +1 800-653-5374
[email protected]

SOURCE: Affinity Mediaworks

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
01/10 Corix Responds to Minority Shareholders Lawsuit
2017 Corix Bioscience Inc. Repays $375,000 Note
2017 CORIX BIOSCIENCE : Unique Acquisition Paves the Way for Global Sales -- CFN Medi..
2017 CORIX BIOSCIENCE : Purchases Pharmaceutical Development Corp LTD
2017 CORIX BIOSCIENCE : Looks to Standardize CBD for Athletes -- CFN Media
2017 CORIX BIOSCIENCE : Inc. to Purchase 46,060 Square Foot Research Facility
2017 CORIX BIOSCIENCE : Enters California Cannabis Market Adding 3 Licenses
2017 CORIX BIOSCIENCE : Inc. Signs Major Sales Agreement for up to 22,000 Pounds of H..
2017 CORIX BIOSCIENCE : Announces New Tissue Culture and Research Lab
More news
Michael Ogburn Chairman, President, CEO, CFO & Treasurer
Joseph Curtis Chief Operating Officer & Head-FDA Compliance
Brian Werner Director
Sean Zarinegar Director
Les F. Gutierrez Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.30%104 801
GENMAB11.42%11 532
EXELIXIS, INC.-0.07%8 772